Comparative evaluation of the effects of different DPP-4 inhibitors on lipid metabolism will be required in the future to determine the best agent for lipid control in patients with type 2 diabetes and hyperlipidemia. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.